首页 > 最新文献

Mediterranean Journal of Rheumatology最新文献

英文 中文
The Long-Term Outcomes of Pulmonary Hypertension in Systemic Lupus Erythematosus (SLE-PAH) Vary Among Different Autoantibody-Based Clusters: An Observational, Longitudinal Study Conducted at a Single Centre in India. 系统性红斑狼疮(SLE-PAH)肺动脉高压的长期预后在不同的自身抗体集群中有所不同:一项在印度单一中心进行的观察性纵向研究。
Q4 Medicine Pub Date : 2025-08-26 eCollection Date: 2025-12-01 DOI: 10.31138/mjr.060425.acl
Ritasman Baisya, Yerram Keerthi Vardhan, Murthy Gsr, Yerram Vivek Vardhan, Liza Rajasekhar

Background: Pulmonary arterial hypertension (PAH) is often overlooked in systemic lupus erythematosus (SLE) patients. However, the association between SLE and PAH is gaining attention due to unique mechanisms and treatment responses.

Objectives: This study aims to categorise SLE-PAH patients by autoantibody profiles and evaluate long-term outcomes, including mortality and changes in PAH over 12 months.

Method: A hospital-based investigation included SLE patients diagnosed with PAH. We analysed mortality, PAH resolution, increases in anti-PAH therapy, and follow-up right ventricular systolic pressure (RVSP) over 12 months. K-means cluster analysis was used for clustering, with regression analyses predicting mortality.

Result: Analysing 111 SLE PAH patients revealed three clusters: Cluster 1 (CL1)-Sm-RNP positive (n=48), Cluster 2 (CL2)-no specific autoantibodies (n=36), and Cluster 3 (CL3)-multiple autoantibody positivity (n=27) (Smith, Sm-RNP, nucleosome, histone). Nephritis was significant in CL3 with multiple antibody positivity compared to CL1 and CL2 (p=0.01). CL1 showed a higher baseline mean RVSP (64.5 ± 19.1 (CL1) vs 57.5 ± 12.6 (CL2) vs 50.9 ± 12, p=0.002) and more frequent use of dual anti-PAH therapy (p=0.000). CL2, without any specific antibody, had an earlier onset of PAH (p=0.04). Significant improvement in PAH after withdrawing anti-PAH medication was noted in Cluster 3 (p=0.00). Regression analysis showed that aggressive anti-PAH therapy lowers PAH-related mortality (p=0.01), while nephritis (p=0.012) and positive dsDNA (p=0.009) correlate with higher mortality.

Conclusion: This study is the first to analyse SLE-PAH through cluster-based methods. Sm-RNP antibodies indicate more severe disease needing dual therapy, while multiple positive antibodies suggest a better prognosis, with most patients achieving PAH resolution.

背景:肺动脉高压(PAH)在系统性红斑狼疮(SLE)患者中经常被忽视。然而,SLE和PAH之间的关联由于其独特的机制和治疗反应而受到关注。目的:本研究旨在通过自身抗体谱对SLE-PAH患者进行分类,并评估长期预后,包括死亡率和PAH在12个月内的变化。方法:一项以医院为基础的调查,包括诊断为PAH的SLE患者。我们分析了死亡率、PAH消退、抗PAH治疗的增加以及随访12个月的右心室收缩压(RVSP)。聚类采用k均值聚类分析,回归分析预测死亡率。结果:分析111例SLE PAH患者,发现3组:第1组(CL1)-Sm-RNP阳性(n=48),第2组(CL2)-无特异性自身抗体(n=36),第3组(CL3)-多重自身抗体阳性(n=27) (Smith, Sm-RNP,核小体,组蛋白)。多抗体阳性的CL3组肾炎发生率明显高于CL1和CL2组(p=0.01)。CL1显示更高的基线平均RVSP(64.5±19.1 (CL1) vs 57.5±12.6 (CL2) vs 50.9±12,p=0.002)和更频繁地使用双重抗pah治疗(p=0.000)。无特异性抗体的CL2更早发生PAH (p=0.04)。第3组患者在停用抗PAH药物后PAH明显改善(p=0.00)。回归分析显示,积极的抗pah治疗降低了pah相关的死亡率(p=0.01),而肾炎(p=0.012)和dsDNA阳性(p=0.009)与更高的死亡率相关。结论:本研究首次采用基于聚类的方法对sle1 - pah进行分析。Sm-RNP抗体提示病情更严重,需要双重治疗,而多种抗体阳性提示预后更好,大多数患者获得PAH消退。
{"title":"The Long-Term Outcomes of Pulmonary Hypertension in Systemic Lupus Erythematosus (SLE-PAH) Vary Among Different Autoantibody-Based Clusters: An Observational, Longitudinal Study Conducted at a Single Centre in India.","authors":"Ritasman Baisya, Yerram Keerthi Vardhan, Murthy Gsr, Yerram Vivek Vardhan, Liza Rajasekhar","doi":"10.31138/mjr.060425.acl","DOIUrl":"10.31138/mjr.060425.acl","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary arterial hypertension (PAH) is often overlooked in systemic lupus erythematosus (SLE) patients. However, the association between SLE and PAH is gaining attention due to unique mechanisms and treatment responses.</p><p><strong>Objectives: </strong>This study aims to categorise SLE-PAH patients by autoantibody profiles and evaluate long-term outcomes, including mortality and changes in PAH over 12 months.</p><p><strong>Method: </strong>A hospital-based investigation included SLE patients diagnosed with PAH. We analysed mortality, PAH resolution, increases in anti-PAH therapy, and follow-up right ventricular systolic pressure (RVSP) over 12 months. K-means cluster analysis was used for clustering, with regression analyses predicting mortality.</p><p><strong>Result: </strong>Analysing 111 SLE PAH patients revealed three clusters: Cluster 1 (CL1)-Sm-RNP positive (n=48), Cluster 2 (CL2)-no specific autoantibodies (n=36), and Cluster 3 (CL3)-multiple autoantibody positivity (n=27) (Smith, Sm-RNP, nucleosome, histone). Nephritis was significant in CL3 with multiple antibody positivity compared to CL1 and CL2 (p=0.01). CL1 showed a higher baseline mean RVSP (64.5 ± 19.1 (CL1) vs 57.5 ± 12.6 (CL2) vs 50.9 ± 12, p=0.002) and more frequent use of dual anti-PAH therapy (p=0.000). CL2, without any specific antibody, had an earlier onset of PAH (p=0.04). Significant improvement in PAH after withdrawing anti-PAH medication was noted in Cluster 3 (p=0.00). Regression analysis showed that aggressive anti-PAH therapy lowers PAH-related mortality (p=0.01), while nephritis (p=0.012) and positive dsDNA (p=0.009) correlate with higher mortality.</p><p><strong>Conclusion: </strong>This study is the first to analyse SLE-PAH through cluster-based methods. Sm-RNP antibodies indicate more severe disease needing dual therapy, while multiple positive antibodies suggest a better prognosis, with most patients achieving PAH resolution.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 4","pages":"594-599"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effectiveness of Infliximab in Treating Vascular Manifestations of Behçet's Disease: A Systematic Review and Meta-Analysis. 英夫利昔单抗治疗behet病血管表现的有效性:系统回顾和荟萃分析。
Q4 Medicine Pub Date : 2025-08-26 eCollection Date: 2025-12-01 DOI: 10.31138/mjr.080325.tav
Aymane Bennani, El Khalil Benmansour, Khalid Serraj

Objective: Our study aims to evaluate the effectiveness of anti-tumour-necrosis-factor Infliximab (IFX) in treating patients with severe and/or refractory vascular manifestations of Behçet's disease (BD) through a systematic review and meta-analysis.

Methods: We searched PubMed, Scopus, Web of Science, and Cochrane Library databases for eligible studies. Meta-analysis of proportions was performed. Heterogeneity was assessed with Cochrane's Q test and I2 statistics. Random effects models were used for all statistical analyses which were conducted on R software (version 4.4.2), PROSPERO registry number CRD42025640970.

Results: Of the 2127 results initially identified, 11 studies with a total of 284 patients were included in the final analysis. Infliximab induced complete vascular response in 78.17% of patients (95% CI 63.11-90.61). The remission rates in the subgroups of patients with pulmonary artery aneurysm and the venous thrombosis events were respectively 99.13% (95% CI 86.21-100) and 86.48 % (95% CI 71.81-97.15).

Conclusion: Our systematic review and meta-analysis support the use of infliximab in patients with severe and/or refractory vascular Behçet's disease, particularly in cases involving pulmonary artery aneurysms.

目的:本研究旨在通过系统回顾和荟萃分析,评估抗肿瘤坏死因子英夫利昔单抗(IFX)治疗严重和/或难治性血管表现的behet病(BD)患者的有效性。方法:检索PubMed、Scopus、Web of Science和Cochrane Library数据库,寻找符合条件的研究。对比例进行meta分析。采用Cochrane’s Q检验和I2统计量评估异质性。所有统计分析均采用随机效应模型,采用R软件(版本4.4.2),PROSPERO注册号CRD42025640970。结果:在最初确定的2127个结果中,11项研究共284例患者被纳入最终分析。英夫利昔单抗诱导78.17%的患者血管完全缓解(95% CI 63.11-90.61)。肺动脉动脉瘤和静脉血栓事件亚组缓解率分别为99.13% (95% CI 86.21-100)和86.48% (95% CI 71.81-97.15)。结论:我们的系统评价和荟萃分析支持英夫利昔单抗在严重和/或难治性血管性behet病患者中的应用,特别是在涉及肺动脉动脉瘤的病例中。
{"title":"The Effectiveness of Infliximab in Treating Vascular Manifestations of Behçet's Disease: A Systematic Review and Meta-Analysis.","authors":"Aymane Bennani, El Khalil Benmansour, Khalid Serraj","doi":"10.31138/mjr.080325.tav","DOIUrl":"10.31138/mjr.080325.tav","url":null,"abstract":"<p><strong>Objective: </strong>Our study aims to evaluate the effectiveness of anti-tumour-necrosis-factor Infliximab (IFX) in treating patients with severe and/or refractory vascular manifestations of Behçet's disease (BD) through a systematic review and meta-analysis.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, Web of Science, and Cochrane Library databases for eligible studies. Meta-analysis of proportions was performed. Heterogeneity was assessed with Cochrane's Q test and I<sup>2</sup> statistics. Random effects models were used for all statistical analyses which were conducted on R software (version 4.4.2), PROSPERO registry number CRD42025640970<i>.</i></p><p><strong>Results: </strong>Of the 2127 results initially identified, 11 studies with a total of 284 patients were included in the final analysis. Infliximab induced complete vascular response in 78.17% of patients (95% CI 63.11-90.61). The remission rates in the subgroups of patients with pulmonary artery aneurysm and the venous thrombosis events were respectively 99.13% (95% CI 86.21-100) and 86.48 % (95% CI 71.81-97.15).</p><p><strong>Conclusion: </strong>Our systematic review and meta-analysis support the use of infliximab in patients with severe and/or refractory vascular Behçet's disease, particularly in cases involving pulmonary artery aneurysms.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 4","pages":"539-546"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Great Vasculitis Pretenders: Mycotic Pseudoaneurysm, Aortitis with Occlusive Iliac Thrombus, and Paraneoplastic Aortitis. A Case-Based Review. 假性大血管炎:真菌性假性动脉瘤、动脉炎伴闭塞性髂血栓和副肿瘤主动脉炎。基于案例的审查。
Q4 Medicine Pub Date : 2025-08-20 eCollection Date: 2025-09-01 DOI: 10.31138/mjr.220125.era
Cristine Kuzhuppilly Arcilla, Tomas Marek, Gurjit Kaeley

Vasculitides encompass a group of inflammatory diseases that affect blood vessels, leading to vessel wall thickening, ischemia, and potential organ damage. While rare, the prevalence of vasculitis has increased in recent years. Its presentation often mimics infectious and paraneoplastic diseases, requiring the identification of risk factors and individualised diagnostic workup. Delayed or inaccurate diagnosis of vasculitis can result in significant morbidity, vascular complications, and death since specific therapy depends on underlying aetiology and pathology. This case series highlights three patients presenting with mycotic pseudoaneurysm, infectious occlusive iliac thrombus relative to a chronic state of immunosuppression, infections, and malignancy associated with Crohn-related fistulas, Campylobacter fetus bacteraemia, and paraneoplastic aetiologies, resulting in poor patient outcomes. It is crucial to distinguish primary vasculitis from secondary aetiologies and mimickers, as misdiagnosis can lead to unnecessary, potentially harmful treatments and delay in surgical interventions if indicated.

血管粥样硬化包括一组影响血管的炎症性疾病,导致血管壁增厚、缺血和潜在的器官损伤。虽然罕见,但近年来血管炎的患病率有所增加。它的表现通常与传染病和副肿瘤疾病相似,需要确定危险因素和个性化的诊断检查。由于具体治疗取决于潜在的病因和病理,延迟或不准确的血管炎诊断可导致显著的发病率、血管并发症和死亡。本病例系列突出了三例患者,表现为真菌性假性动脉瘤,感染性闭塞性髂血栓,慢性免疫抑制状态,感染和与克罗恩相关瘘管相关的恶性肿瘤,弯曲杆菌胎儿菌血症和副肿瘤病因,导致患者预后不佳。将原发性血管炎与继发性病因和模仿物区分开来是至关重要的,因为误诊可能导致不必要的、潜在有害的治疗和延迟手术干预。
{"title":"The Great Vasculitis Pretenders: Mycotic Pseudoaneurysm, Aortitis with Occlusive Iliac Thrombus, and Paraneoplastic Aortitis. A Case-Based Review.","authors":"Cristine Kuzhuppilly Arcilla, Tomas Marek, Gurjit Kaeley","doi":"10.31138/mjr.220125.era","DOIUrl":"10.31138/mjr.220125.era","url":null,"abstract":"<p><p>Vasculitides encompass a group of inflammatory diseases that affect blood vessels, leading to vessel wall thickening, ischemia, and potential organ damage. While rare, the prevalence of vasculitis has increased in recent years. Its presentation often mimics infectious and paraneoplastic diseases, requiring the identification of risk factors and individualised diagnostic workup. Delayed or inaccurate diagnosis of vasculitis can result in significant morbidity, vascular complications, and death since specific therapy depends on underlying aetiology and pathology. This case series highlights three patients presenting with mycotic pseudoaneurysm, infectious occlusive iliac thrombus relative to a chronic state of immunosuppression, infections, and malignancy associated with Crohn-related fistulas, <i>Campylobacter fetus</i> bacteraemia, and paraneoplastic aetiologies, resulting in poor patient outcomes. It is crucial to distinguish primary vasculitis from secondary aetiologies and mimickers, as misdiagnosis can lead to unnecessary, potentially harmful treatments and delay in surgical interventions if indicated.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"488-496"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What Large Language Models offer about Familial Mediterranean Fever: An Analysis of Quality, Readability, Completeness, and Accuracy. 什么大型语言模型提供家族地中海热:质量,可读性,完整性和准确性的分析。
Q4 Medicine Pub Date : 2025-08-20 eCollection Date: 2025-09-01 DOI: 10.31138/mjr.261224.hfm
Burak Tayyip Dede, Didem Erdem Gürsoy, Muhammed Oğuz, Bülent Alyanak, Fatih Bağcıer

Background: The aim of this study was to evaluate the quality, completeness, accuracy, and readability of Large Language Models (LLM) responses to 25 popular questions about Familial Mediterranean Fever (FMF).

Methods: The readability of the responses of LLMs (ChatGPT-4, Copilot, Gemini) was assessed by Flesch Reading Ease Score (FRES) and Flesch-Kincaid Grade (FKG). The Ensuring Quality Information for Patients (EQIP) tool was used to assess the quality. To assess the completeness and accuracy of responses, 3-point and 5-point Likert scales were used, respectively.

Results: The mean FRES scores of LLMs ranged between 29.80 and 35.66. The FKG scores ranged between 12.36 and 13.72. The mean accuracy scores of LLMs ranged between 4.88 and 4.96. No significant difference was found between the LLM groups regarding accuracy and readability scores (p>0.05). The mean completeness scores of LLMs ranged between 2.36 and 2.84. ChatGPT-4 was the leading LLM in completeness scores according to the Likert scale, and the difference between LLM groups was statistically significant (p=0.006). Gemini performed better in the quality analysis with the EQIP tool, and there was a statistically significant difference between the LLM groups (p<0.001).

Conclusion: In this study, LLMs performed acceptably in accuracy and completeness. However, there are serious concerns about their readability and quality. To improve health information, LLM developers should include more diverse data sources in the training sets of the models. Moreover, the ability of LLMs to provide readability features that are adaptable to the level of education could be an important innovation in this field.

背景:本研究的目的是评估大语言模型(LLM)对家族性地中海热(FMF) 25个常见问题的回答的质量、完整性、准确性和可读性。方法:采用Flesch Reading Ease Score (FRES)和Flesch- kincaid Grade (FKG)对法学硕士(ChatGPT-4、Copilot、Gemini)的答题可读性进行评价。采用患者质量保证信息(EQIP)工具进行质量评价。为了评估回答的完整性和准确性,分别使用3分制和5分制李克特量表。结果:LLMs的平均FRES评分在29.80 ~ 35.66之间。FKG得分在12.36到13.72之间。llm的平均准确率评分在4.88 ~ 4.96之间。LLM组在准确性和可读性评分方面无显著差异(p < 0.05)。llm的平均完备性评分在2.36 ~ 2.84之间。根据Likert量表,ChatGPT-4是LLM完整性得分最高的LLM, LLM组间差异有统计学意义(p=0.006)。Gemini在EQIP工具质量分析中表现较好,LLM组间差异有统计学意义(p)。结论:在本研究中,LLM在准确性和完整性方面表现良好。然而,对于它们的可读性和质量存在严重的担忧。为了改进健康信息,LLM开发人员应该在模型的训练集中包括更多样化的数据源。此外,法学硕士提供可适应教育水平的可读性特征的能力可能是该领域的重要创新。
{"title":"What Large Language Models offer about Familial Mediterranean Fever: An Analysis of Quality, Readability, Completeness, and Accuracy.","authors":"Burak Tayyip Dede, Didem Erdem Gürsoy, Muhammed Oğuz, Bülent Alyanak, Fatih Bağcıer","doi":"10.31138/mjr.261224.hfm","DOIUrl":"10.31138/mjr.261224.hfm","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate the quality, completeness, accuracy, and readability of Large Language Models (LLM) responses to 25 popular questions about Familial Mediterranean Fever (FMF).</p><p><strong>Methods: </strong>The readability of the responses of LLMs (ChatGPT-4, Copilot, Gemini) was assessed by Flesch Reading Ease Score (FRES) and Flesch-Kincaid Grade (FKG). The Ensuring Quality Information for Patients (EQIP) tool was used to assess the quality. To assess the completeness and accuracy of responses, 3-point and 5-point Likert scales were used, respectively.</p><p><strong>Results: </strong>The mean FRES scores of LLMs ranged between 29.80 and 35.66. The FKG scores ranged between 12.36 and 13.72. The mean accuracy scores of LLMs ranged between 4.88 and 4.96. No significant difference was found between the LLM groups regarding accuracy and readability scores (p>0.05). The mean completeness scores of LLMs ranged between 2.36 and 2.84. ChatGPT-4 was the leading LLM in completeness scores according to the Likert scale, and the difference between LLM groups was statistically significant (p=0.006). Gemini performed better in the quality analysis with the EQIP tool, and there was a statistically significant difference between the LLM groups (p<0.001).</p><p><strong>Conclusion: </strong>In this study, LLMs performed acceptably in accuracy and completeness. However, there are serious concerns about their readability and quality. To improve health information, LLM developers should include more diverse data sources in the training sets of the models. Moreover, the ability of LLMs to provide readability features that are adaptable to the level of education could be an important innovation in this field.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"410-416"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Performance of ANCA Testing Across Three Platforms with and without Coexisting ANA Positivity: Experience from a Tertiary Healthcare Centre in India. 有和没有共存的ANA阳性的三个平台上的ANCA测试的诊断性能:来自印度三级医疗中心的经验。
Q4 Medicine Pub Date : 2025-08-20 eCollection Date: 2025-12-01 DOI: 10.31138/mjr.130225.eft
Neha Rai, Shamshad Ahmad, Saurabh Karmakar, Divendu Bhushan, Pragya Kumar, Ayan Banerjee, Mukunda Kumar, Akash Bansal, Anurag Kumar, Rajiv Ranjan Sinha, Mala Mahto

Background: Indirect immunofluorescence (IIF) is a useful diagnostic modality for anti-neutrophilic cytoplasmic antibody (ANCA) detection in ANCA associated with vasculitis and diseases beyond vasculitis. As per latest guidelines, the IIF has been replaced by enzyme-linked immunosorbent assay (ELISA) as first line of screening for ANCA. The study intends to evaluate the performance of IIF and ELISA for ANCA testing and the impact of antinuclear antibody (ANA) positivity on ANCA reporting across these platforms.

Methods: A total of 70 samples, 53 ANA positive and 17 ANA negative, were included in the study. They were tested for ANCA across three different platforms based on IIF and ELISA. An attempt was also made to identify if presence and pattern of ANA affected ANCA reporting across any particular platform.

Results: The impact of ANA positivity on ANCA reporting was done using logistic regression analysis. An evaluation of the sensitivity and specificity of each ANCA testing platform was done considering ELISA as the reference method. Subgroup analyses were conducted on the basis of ANA patterns to further know their impact on the specificity and sensitivity of ANCA tests. The use of a 3-biochip combination for ANCA reporting by IIF resulted in a significant reduction of false positive ANCA due to ANA when a combination of ethanol and formalin fixed granulocytes were used.

Conclusion: There are notable differences in ANCA diagnostics between IIF based on ethanol fixed granulocytes alone and combination of three biochip. However, the addition of Proteinase 3/myeloperoxidase (PR3/MPO) dots to the 3-chip combination did not offer any added advantage.

背景:间接免疫荧光(IIF)检测抗中性粒细胞胞浆抗体(ANCA)是一种有用的诊断方式,用于检测ANCA与血管炎和血管炎以外的疾病相关。根据最新指南,IIF已被酶联免疫吸附试验(ELISA)取代,成为ANCA筛查的一线方法。本研究旨在评估IIF和ELISA检测ANCA的性能,以及抗核抗体(ANA)阳性对这些平台上ANCA报告的影响。方法:共收集70例样本,其中ANA阳性53例,ANA阴性17例。他们基于IIF和ELISA在三个不同的平台上进行了ANCA测试。还试图确定ANA的存在和模式是否会影响任何特定平台上的ANCA报告。结果:采用logistic回归分析ANA阳性对ANCA报告的影响。以ELISA为参考,评价各检测平台的敏感性和特异性。在ANA模式的基础上进行亚组分析,进一步了解其对ANCA检测的特异性和敏感性的影响。当使用乙醇和福尔马林固定的粒细胞组合时,IIF报告ANCA时使用3-生物芯片组合导致ANA假阳性ANCA的显著减少。结论:单独使用乙醇固定粒细胞与联合使用三种生物芯片对IIF的ANCA诊断有显著差异。然而,在3芯片组合中添加蛋白酶3/髓过氧化物酶(PR3/MPO)点并没有提供任何额外的优势。
{"title":"Diagnostic Performance of ANCA Testing Across Three Platforms with and without Coexisting ANA Positivity: Experience from a Tertiary Healthcare Centre in India.","authors":"Neha Rai, Shamshad Ahmad, Saurabh Karmakar, Divendu Bhushan, Pragya Kumar, Ayan Banerjee, Mukunda Kumar, Akash Bansal, Anurag Kumar, Rajiv Ranjan Sinha, Mala Mahto","doi":"10.31138/mjr.130225.eft","DOIUrl":"10.31138/mjr.130225.eft","url":null,"abstract":"<p><strong>Background: </strong>Indirect immunofluorescence (IIF) is a useful diagnostic modality for anti-neutrophilic cytoplasmic antibody (ANCA) detection in ANCA associated with vasculitis and diseases beyond vasculitis. As per latest guidelines, the IIF has been replaced by enzyme-linked immunosorbent assay (ELISA) as first line of screening for ANCA. The study intends to evaluate the performance of IIF and ELISA for ANCA testing and the impact of antinuclear antibody (ANA) positivity on ANCA reporting across these platforms.</p><p><strong>Methods: </strong>A total of 70 samples, 53 ANA positive and 17 ANA negative, were included in the study. They were tested for ANCA across three different platforms based on IIF and ELISA. An attempt was also made to identify if presence and pattern of ANA affected ANCA reporting across any particular platform.</p><p><strong>Results: </strong>The impact of ANA positivity on ANCA reporting was done using logistic regression analysis. An evaluation of the sensitivity and specificity of each ANCA testing platform was done considering ELISA as the reference method. Subgroup analyses were conducted on the basis of ANA patterns to further know their impact on the specificity and sensitivity of ANCA tests. The use of a 3-biochip combination for ANCA reporting by IIF resulted in a significant reduction of false positive ANCA due to ANA when a combination of ethanol and formalin fixed granulocytes were used.</p><p><strong>Conclusion: </strong>There are notable differences in ANCA diagnostics between IIF based on ethanol fixed granulocytes alone and combination of three biochip. However, the addition of Proteinase 3/myeloperoxidase (PR3/MPO) dots to the 3-chip combination did not offer any added advantage.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 4","pages":"584-593"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interstitial Lung Disease and Pulmonary Arterial Hypertension Screening Practices in Systemic Sclerosis: Survey Insights of Rheumatologists in the Middle East and North Africa Region. 系统性硬化症的间质性肺病和肺动脉高压筛查实践:中东和北非地区风湿病学家的调查见解。
Q4 Medicine Pub Date : 2025-08-18 eCollection Date: 2025-09-01 DOI: 10.31138/mjr.211224.alf
Rajaie Namas, Sarah Al Qassimi, Jawahir Alameri, Samar Al Emadi, Nelly Ziade, Ahlam Almarzooqi, Farida Al Balushi, Mohammed A Omair, Taha Qardaghi, Yasameen Abbas Humadi, Mohamed Alawlaqi, Hanan Al Rayes, Saadeya Naji, Fatima Haji, Fajer Altamimi, Mansour Alazmi, Hani Shatnawi, Waleed Hafiz, Deena Ahmed, Mariam Almansoori, Jamal Al Saleh, Hazem Rifaai, Mahdi Abusalameh, Zaki Abou Zahr, Hiba Khogali, Sehriban Diab, Maha Anbar, Adeeba Al Herz, Amal Elganzoury, Shaima Ewila, Basant Elnady, Wafa Madanat, Imad Uthman, Asia Mubashir, Mohamed Elarabi, Suzan Attar

Background: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are significant causes of morbidity and mortality in systemic sclerosis (SSc). Our objective was to determine screening practices for ILD and PAH in patients with SSc among rheumatologists in the Middle East and North Africa (MENA) region.

Methods: An online questionnaire was distributed to rheumatologists across the MENA region. Participants were asked to estimate the proportion of SSc patients in their practice, indicate whether they screen for ILD and PAH, and specify how often they utilise screening modalities, including chest X-ray (CXR), high-resolution CT (HRCT), pulmonary function tests (PFTs), echocardiograms (ECHO), and the use of the DETECT algorithm. Data were analysed using descriptive statistics, with p-values ≤0.05 regarded as statistically significant.

Results: 394 respondents completed the questionnaire from 17 MENA countries. 389 (98.73%) reported screening for ILD, and 369 (93.65%) screened for PAH. 270 respondents performed screening at the time of SSc diagnosis (68.53%). Screening approaches for ILD included CXR (211, 53.55%), HRCT (321, 81.47%), and PFTs (299, 75.89%), while PAH screening included ECHO (346, 87.82%), and the DETECT algorithm (26.14%). Statistical differences were observed in the average number of SSc patients seen per year (p=0.0008), gender of respondents (p=0.02), current age (p=0.02), background training (p<0.00001), use of ECHO as PAH screening (p=0.01), and the DETECT algorithm (p=0.000017) between SSc experts and non-SSc experts.

Conclusions: Our findings reflect real-world screening practices in SSc patients, emphasising discrepancies which could stem from variations in clinical training, resource availability, or institutional protocols across healthcare settings.

背景:间质性肺疾病(ILD)和肺动脉高压(PAH)是系统性硬化症(SSc)发病和死亡的重要原因。我们的目的是确定中东和北非(MENA)地区风湿病学家对SSc患者ILD和PAH的筛查做法。方法:向中东和北非地区的风湿病学家分发在线问卷。参与者被要求估计SSc患者在实践中的比例,表明他们是否筛查ILD和PAH,并说明他们使用筛查方式的频率,包括胸部x射线(CXR)、高分辨率CT (HRCT)、肺功能检查(PFTs)、超声心动图(ECHO)和DETECT算法的使用。资料分析采用描述性统计,以p值≤0.05为有统计学意义。结果:来自17个中东和北非国家的394名受访者完成了问卷调查。389例(98.73%)报告了ILD筛查,369例(93.65%)报告了PAH筛查。270名受访者在SSc诊断时进行了筛查(68.53%)。ILD筛查方法包括CXR(211例,53.55%)、HRCT(321例,81.47%)和PFTs(299例,75.89%),PAH筛查方法包括ECHO(346例,87.82%)和DETECT算法(26.14%)。在每年SSc患者的平均人数(p=0.0008)、受访者性别(p=0.02)、当前年龄(p=0.02)、背景培训(p)等方面观察到统计学差异。结论:我们的研究结果反映了SSc患者的真实筛查实践,强调差异可能源于临床培训、资源可用性或医疗保健机构协议的差异。
{"title":"Interstitial Lung Disease and Pulmonary Arterial Hypertension Screening Practices in Systemic Sclerosis: Survey Insights of Rheumatologists in the Middle East and North Africa Region.","authors":"Rajaie Namas, Sarah Al Qassimi, Jawahir Alameri, Samar Al Emadi, Nelly Ziade, Ahlam Almarzooqi, Farida Al Balushi, Mohammed A Omair, Taha Qardaghi, Yasameen Abbas Humadi, Mohamed Alawlaqi, Hanan Al Rayes, Saadeya Naji, Fatima Haji, Fajer Altamimi, Mansour Alazmi, Hani Shatnawi, Waleed Hafiz, Deena Ahmed, Mariam Almansoori, Jamal Al Saleh, Hazem Rifaai, Mahdi Abusalameh, Zaki Abou Zahr, Hiba Khogali, Sehriban Diab, Maha Anbar, Adeeba Al Herz, Amal Elganzoury, Shaima Ewila, Basant Elnady, Wafa Madanat, Imad Uthman, Asia Mubashir, Mohamed Elarabi, Suzan Attar","doi":"10.31138/mjr.211224.alf","DOIUrl":"10.31138/mjr.211224.alf","url":null,"abstract":"<p><strong>Background: </strong>Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are significant causes of morbidity and mortality in systemic sclerosis (SSc). Our objective was to determine screening practices for ILD and PAH in patients with SSc among rheumatologists in the Middle East and North Africa (MENA) region.</p><p><strong>Methods: </strong>An online questionnaire was distributed to rheumatologists across the MENA region. Participants were asked to estimate the proportion of SSc patients in their practice, indicate whether they screen for ILD and PAH, and specify how often they utilise screening modalities, including chest X-ray (CXR), high-resolution CT (HRCT), pulmonary function tests (PFTs), echocardiograms (ECHO), and the use of the DETECT algorithm. Data were analysed using descriptive statistics, with p-values ≤0.05 regarded as statistically significant.</p><p><strong>Results: </strong>394 respondents completed the questionnaire from 17 MENA countries. 389 (98.73%) reported screening for ILD, and 369 (93.65%) screened for PAH. 270 respondents performed screening at the time of SSc diagnosis (68.53%). Screening approaches for ILD included CXR (211, 53.55%), HRCT (321, 81.47%), and PFTs (299, 75.89%), while PAH screening included ECHO (346, 87.82%), and the DETECT algorithm (26.14%). Statistical differences were observed in the average number of SSc patients seen per year (p=0.0008), gender of respondents (p=0.02), current age (p=0.02), background training (p<0.00001), use of ECHO as PAH screening (p=0.01), and the DETECT algorithm (p=0.000017) between SSc experts and non-SSc experts.</p><p><strong>Conclusions: </strong>Our findings reflect real-world screening practices in SSc patients, emphasising discrepancies which could stem from variations in clinical training, resource availability, or institutional protocols across healthcare settings.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"392-402"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual Dysfunction in Systemic Autoimmune Rheumatic Diseases: Prevalence, Impact, and Management Strategies. 系统性自身免疫性风湿病的性功能障碍:患病率、影响和管理策略。
Q4 Medicine Pub Date : 2025-08-18 eCollection Date: 2025-09-01 DOI: 10.31138/mjr.170225.iap
Monisha In, Nilanjana Dutta, Harshwardhan Patil, Mahabaleshwar Mamadapur, Veerendra Arakalavadi Guruswamy, Pavan Kumar M R

Background: Systemic autoimmune rheumatic diseases (SARDs) profoundly impact patients' quality of life (QoL) including sexual health, yet sexual dysfunction (SD) remains underrecognised in clinical care. Contributing factors include chronic pain, fatigue, joint stiffness, hormonal imbalances and psychological distress.

Objective: This review evaluates the prevalence, impact, and management of SD in patients with systemic autoimmune rheumatic diseases (SARDs), including Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Sjögren's disease (SjD), and Systemic Sclerosis (SSc), as well as the related chronic condition Fibromyalgia Syndrome (FMS).

Methods: A systematic literature review was conducted using PubMed, Web of Science, and Scopus with relevant MeSH terms. Studies reporting SD in SARDs were included, with sexual function commonly assessed via the Female Sexual Function Index (FSFI) and International Index of Erectile Function (IIEF).

Results: SD prevalence ranged from 30% to 90%, varying by disease and gender. Up to 90% of women with SLE reported reduced desire and arousal. RA affected 30-70% of patients, with pain and depression as key drivers. In AS, erectile dysfunction affected 41-58% of men, influenced by age and disease duration. Over 56% of women with SjD experienced SD, often linked to vaginal dryness. SSc-induced fibrosis led to erectile dysfunction in 80% of men. FMS showed a 63% SD rate, associated with chronic pain and psychological burden.

Conclusion: SD is highly prevalent yet underaddressed in SARDs. A multidisciplinary approach combining pain management, psychological support, hormonal therapy, and patient education is essential.

背景:系统性自身免疫性风湿病(SARDs)深刻影响患者的生活质量(QoL),包括性健康,但性功能障碍(SD)在临床护理中仍未得到充分认识。诱发因素包括慢性疼痛、疲劳、关节僵硬、荷尔蒙失衡和心理困扰。目的:本综述评估系统性自身免疫性风湿性疾病(SARDs)患者SD的患病率、影响和管理,包括系统性红斑狼疮(SLE)、类风湿性关节炎(RA)、强直性脊柱炎(AS)、Sjögren病(SjD)和系统性硬化症(SSc),以及相关的慢性疾病纤维肌痛综合征(FMS)。方法:系统查阅PubMed、Web of Science、Scopus等相关MeSH术语的文献。研究报告了sard中的SD,性功能通常通过女性性功能指数(FSFI)和国际勃起功能指数(IIEF)进行评估。结果:SD患病率从30%到90%不等,因疾病和性别而异。高达90%的SLE女性报告性欲和性唤起降低。RA影响了30-70%的患者,疼痛和抑郁是主要驱动因素。在AS患者中,41-58%的男性存在勃起功能障碍,受年龄和疾病持续时间的影响。超过56%的女性患有性功能障碍,通常与阴道干燥有关。ssc诱导的纤维化导致80%的男性勃起功能障碍。FMS显示63%的SD率,与慢性疼痛和心理负担有关。结论:SD在SARDs中非常普遍,但未得到充分重视。结合疼痛管理、心理支持、激素治疗和患者教育的多学科方法是必不可少的。
{"title":"Sexual Dysfunction in Systemic Autoimmune Rheumatic Diseases: Prevalence, Impact, and Management Strategies.","authors":"Monisha In, Nilanjana Dutta, Harshwardhan Patil, Mahabaleshwar Mamadapur, Veerendra Arakalavadi Guruswamy, Pavan Kumar M R","doi":"10.31138/mjr.170225.iap","DOIUrl":"10.31138/mjr.170225.iap","url":null,"abstract":"<p><strong>Background: </strong>Systemic autoimmune rheumatic diseases (SARDs) profoundly impact patients' quality of life (QoL) including sexual health, yet sexual dysfunction (SD) remains underrecognised in clinical care. Contributing factors include chronic pain, fatigue, joint stiffness, hormonal imbalances and psychological distress.</p><p><strong>Objective: </strong>This review evaluates the prevalence, impact, and management of SD in patients with systemic autoimmune rheumatic diseases (SARDs), including Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Sjögren's disease (SjD), and Systemic Sclerosis (SSc), as well as the related chronic condition Fibromyalgia Syndrome (FMS).</p><p><strong>Methods: </strong>A systematic literature review was conducted using PubMed, Web of Science, and Scopus with relevant MeSH terms. Studies reporting SD in SARDs were included, with sexual function commonly assessed via the Female Sexual Function Index (FSFI) and International Index of Erectile Function (IIEF).</p><p><strong>Results: </strong>SD prevalence ranged from 30% to 90%, varying by disease and gender. Up to 90% of women with SLE reported reduced desire and arousal. RA affected 30-70% of patients, with pain and depression as key drivers. In AS, erectile dysfunction affected 41-58% of men, influenced by age and disease duration. Over 56% of women with SjD experienced SD, often linked to vaginal dryness. SSc-induced fibrosis led to erectile dysfunction in 80% of men. FMS showed a 63% SD rate, associated with chronic pain and psychological burden.</p><p><strong>Conclusion: </strong>SD is highly prevalent yet underaddressed in SARDs. A multidisciplinary approach combining pain management, psychological support, hormonal therapy, and patient education is essential.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"466-478"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing Lung Involvement in Paediatric Rheumatic Diseases: A Retrospective Evaluation of the Limitations of Spirometry. 评估儿童风湿病的肺部损害:肺活量测定法局限性的回顾性评价。
Q4 Medicine Pub Date : 2025-08-18 eCollection Date: 2025-09-01 DOI: 10.31138/mjr.020325.pae
Spyridon Prountzos, Kyveli Chiotopoulou, Katerina Kourtesi, Evdoxia Sapountzi, Dafni Moriki, Elpiniki Kartsiouni, Euthymia Alexopoulou, Konstantinos Douros, Lampros Fotis

Objective: Lung involvement in paediatric rheumatic diseases significantly impacts morbidity and mortality. High-resolution computed tomography (HRCT) is a sensitive diagnostic tool but raises concerns about radiation exposure. Spirometry, a non-invasive and accessible test, is often used to assess pulmonary function, but its accuracy in detecting lung disease in newly diagnosed pediatric rheumatic conditions remains uncertain. This study evaluates spirometry's reliability, using HRCT as the reference standard.

Methods: Patients suspected of lung involvement due to respiratory symptoms or disease prevalence underwent HRCT and pulmonary assessment. A retrospective review of HRCT scans was conducted for 22 pediatric patients diagnosed with rheumatic disease (January 2021-December 2023), all of whom had pathological findings. HRCT was performed using a paired end-inspiratory and forced-expiratory protocol with 1-mm collimation. Radiological findings, including parenchymal opacities, ground-glass opacities, reticular patterns, honeycombing, parenchymal bands, bronchiectasis, peribronchial wall thickening, and air trapping, were assessed. Spirometric values-percent predicted Forced Expiratory Volume in 1 second (ppFEV1), Forced Vital Capacity (ppFVC), and FEV1/FVC ratio-were collected for patients with acceptable flow-volume curves.

Results: Seventeen of 22 patients (77.3%) had technically acceptable spirometry. Compared to HRCT, spirometry demonstrated a sensitivity of 29.4%.

Conclusion: Despite its excellent positive predictive value, spirometry's low sensitivity suggests it may miss early lung involvement in paediatric rheumatic diseases. HRCT remains the preferred diagnostic tool to ensure accurate detection and management, despite radiation concerns.

目的:肺部受累对儿童风湿病的发病率和死亡率有显著影响。高分辨率计算机断层扫描(HRCT)是一种敏感的诊断工具,但引起了对辐射暴露的担忧。肺活量测定法是一种无创且方便的检测方法,常用于评估肺功能,但其在新诊断的儿童风湿病中检测肺部疾病的准确性仍不确定。本研究以HRCT作为参考标准,评价肺活量测定法的可靠性。方法:因呼吸道症状或疾病流行而怀疑肺部受累的患者行HRCT和肺部评估。回顾性分析22例诊断为风湿病的儿童患者(2021年1月- 2023年12月)的HRCT扫描,所有患者均有病理表现。HRCT采用一对吸气末和用力呼气协议,1毫米准直。影像学表现包括实质混浊、毛玻璃混浊、网状、蜂窝状、实质带、支气管扩张、支气管周围壁增厚和气陷。肺活量测量值——预测1秒内用力呼气量(ppFEV1)、用力肺活量(ppFVC)和FEV1/FVC比值的百分比——收集了可接受的流量-容量曲线。结果:22例患者中有17例(77.3%)肺量测定技术可接受。与HRCT相比,肺活量测定的敏感性为29.4%。结论:肺活量测定法虽然具有极好的阳性预测价值,但其敏感性较低,可能会错过儿童风湿病早期肺部受累。尽管存在辐射问题,HRCT仍然是确保准确检测和管理的首选诊断工具。
{"title":"Assessing Lung Involvement in Paediatric Rheumatic Diseases: A Retrospective Evaluation of the Limitations of Spirometry.","authors":"Spyridon Prountzos, Kyveli Chiotopoulou, Katerina Kourtesi, Evdoxia Sapountzi, Dafni Moriki, Elpiniki Kartsiouni, Euthymia Alexopoulou, Konstantinos Douros, Lampros Fotis","doi":"10.31138/mjr.020325.pae","DOIUrl":"10.31138/mjr.020325.pae","url":null,"abstract":"<p><strong>Objective: </strong>Lung involvement in paediatric rheumatic diseases significantly impacts morbidity and mortality. High-resolution computed tomography (HRCT) is a sensitive diagnostic tool but raises concerns about radiation exposure. Spirometry, a non-invasive and accessible test, is often used to assess pulmonary function, but its accuracy in detecting lung disease in newly diagnosed pediatric rheumatic conditions remains uncertain. This study evaluates spirometry's reliability, using HRCT as the reference standard.</p><p><strong>Methods: </strong>Patients suspected of lung involvement due to respiratory symptoms or disease prevalence underwent HRCT and pulmonary assessment. A retrospective review of HRCT scans was conducted for 22 pediatric patients diagnosed with rheumatic disease (January 2021-December 2023), all of whom had pathological findings. HRCT was performed using a paired end-inspiratory and forced-expiratory protocol with 1-mm collimation. Radiological findings, including parenchymal opacities, ground-glass opacities, reticular patterns, honeycombing, parenchymal bands, bronchiectasis, peribronchial wall thickening, and air trapping, were assessed. Spirometric values-percent predicted Forced Expiratory Volume in 1 second (ppFEV1), Forced Vital Capacity (ppFVC), and FEV1/FVC ratio-were collected for patients with acceptable flow-volume curves.</p><p><strong>Results: </strong>Seventeen of 22 patients (77.3%) had technically acceptable spirometry. Compared to HRCT, spirometry demonstrated a sensitivity of 29.4%.</p><p><strong>Conclusion: </strong>Despite its excellent positive predictive value, spirometry's low sensitivity suggests it may miss early lung involvement in paediatric rheumatic diseases. HRCT remains the preferred diagnostic tool to ensure accurate detection and management, despite radiation concerns.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"417-422"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding PFAPA Syndrome in Palestine: A Retrospective Cohort Analysis of Epidemiological and Clinical Data. 了解巴勒斯坦PFAPA综合征:流行病学和临床资料的回顾性队列分析。
Q4 Medicine Pub Date : 2025-07-17 eCollection Date: 2025-09-01 DOI: 10.31138/mjr.110824.qcr
Fawzy M Abunejma, Rose Wazwaz, Romaisa Qawasma, Raghad Abu Dabaat, Oadi N Shrateh

Background: Despite Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy being widely acknowledged as a clinical entity and considered one of the most prevalent autoinflammatory diseases, there remains controversy surrounding its diagnostic criteria. Additionally, the epidemiology of the disease is largely unknown in Palestine. Therefore, the goal of this study is to enhance the understanding of PFAPA syndrome in Palestinian paediatric patients.

Methods: We carried out a retrospective cohort study that included 57 patients diagnosed with PFAPA at hospitals in Hebron, Palestine, specifically at Al-Ahli and the Palestinian Red Crescent Society (PRCS).

Results: The study revealed that PFAPA patients predominantly experienced fever (93.0%) and pharyngotonsillitis (100.0%), with significant associations noted between PFAPA and the presence of pharyngotonsillitis (p=0.006), adenitis (p=0.001), and periodicity. However, no significant associations were found between PFAPA and aphthous stomatitis, abdominal pain, or arthralgia. Patients with PFAPA were significantly less likely to experience diarrhoea (p=0.007) and chest pain (p=0.003). Treatment modalities included steroids (45.6%), tonsillectomy (57.9%), colchicine (91.2%), and antibiotics (56.1%).

Conclusions: This study offers important perception into the clinical characteristics, treatment outcomes, and epidemiology of PFAPA syndrome in Palestinian patients. The findings highlight fever and pharyngotonsillitis as predominant symptoms, along with significant associations observed with adenitis. Treatment approaches involving steroids, tonsillectomy, colchicine, and antibiotics were frequently utilised, with notable responses reported.

背景:尽管周期性发热、口疮性口炎、咽炎和腺病被广泛认为是一种临床实体,并被认为是最常见的自身炎症性疾病之一,但其诊断标准仍存在争议。此外,这种疾病的流行病学在巴勒斯坦基本上是未知的。因此,本研究的目的是提高对巴勒斯坦儿童PFAPA综合征的认识。方法:我们进行了一项回顾性队列研究,纳入了巴勒斯坦希布伦医院诊断为PFAPA的57例患者,特别是在Al-Ahli和巴勒斯坦红新月会(PRCS)。结果:研究显示PFAPA患者主要表现为发热(93.0%)和咽扁桃体炎(100.0%),PFAPA与咽扁桃体炎(p=0.006)、腺炎(p=0.001)和周期性之间存在显著关联。然而,PFAPA与口疮性口炎、腹痛或关节痛之间没有明显的关联。PFAPA患者出现腹泻(p=0.007)和胸痛(p=0.003)的可能性明显降低。治疗方式包括类固醇(45.6%)、扁桃体切除术(57.9%)、秋水仙碱(91.2%)和抗生素(56.1%)。结论:本研究对巴勒斯坦患者PFAPA综合征的临床特征、治疗结果和流行病学提供了重要的认识。研究结果强调发烧和咽扁桃体炎是主要症状,同时与腺炎有显著的联系。治疗方法包括类固醇,扁桃体切除术,秋水仙碱和抗生素经常使用,有显著的反应报道。
{"title":"Understanding PFAPA Syndrome in Palestine: A Retrospective Cohort Analysis of Epidemiological and Clinical Data.","authors":"Fawzy M Abunejma, Rose Wazwaz, Romaisa Qawasma, Raghad Abu Dabaat, Oadi N Shrateh","doi":"10.31138/mjr.110824.qcr","DOIUrl":"10.31138/mjr.110824.qcr","url":null,"abstract":"<p><strong>Background: </strong>Despite Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy being widely acknowledged as a clinical entity and considered one of the most prevalent autoinflammatory diseases, there remains controversy surrounding its diagnostic criteria. Additionally, the epidemiology of the disease is largely unknown in Palestine. Therefore, the goal of this study is to enhance the understanding of PFAPA syndrome in Palestinian paediatric patients.</p><p><strong>Methods: </strong>We carried out a retrospective cohort study that included 57 patients diagnosed with PFAPA at hospitals in Hebron, Palestine, specifically at Al-Ahli and the Palestinian Red Crescent Society (PRCS).</p><p><strong>Results: </strong>The study revealed that PFAPA patients predominantly experienced fever (93.0%) and pharyngotonsillitis (100.0%), with significant associations noted between PFAPA and the presence of pharyngotonsillitis (p=0.006), adenitis (p=0.001), and periodicity. However, no significant associations were found between PFAPA and aphthous stomatitis, abdominal pain, or arthralgia. Patients with PFAPA were significantly less likely to experience diarrhoea (p=0.007) and chest pain (p=0.003). Treatment modalities included steroids (45.6%), tonsillectomy (57.9%), colchicine (91.2%), and antibiotics (56.1%).</p><p><strong>Conclusions: </strong>This study offers important perception into the clinical characteristics, treatment outcomes, and epidemiology of PFAPA syndrome in Palestinian patients. The findings highlight fever and pharyngotonsillitis as predominant symptoms, along with significant associations observed with adenitis. Treatment approaches involving steroids, tonsillectomy, colchicine, and antibiotics were frequently utilised, with notable responses reported.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"387-391"},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Macaroni Sign in Takayasu Arteritis. 高须动脉炎的通心粉征。
Q4 Medicine Pub Date : 2025-07-17 eCollection Date: 2025-09-01 DOI: 10.31138/mjr.050325.atr
Harsh Jain, Sankar J, Kartik Sivasami, Avs Anil Kumar, Neeraj Kumar, Nidhi Goel, Ashish Chandwani, Vivek Vasdev
{"title":"Macaroni Sign in Takayasu Arteritis.","authors":"Harsh Jain, Sankar J, Kartik Sivasami, Avs Anil Kumar, Neeraj Kumar, Nidhi Goel, Ashish Chandwani, Vivek Vasdev","doi":"10.31138/mjr.050325.atr","DOIUrl":"10.31138/mjr.050325.atr","url":null,"abstract":"","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"505-506"},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Mediterranean Journal of Rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1